Pathogenic immunity in systemic lupus erythematosus and atherosclerosis:)Common mechanisms and possible targets for intervention

Journal of Internal Medicine

Volumn 278, Issue 5, 2015, Pages 494-506

  Wigren, M ^a   Nilsson, J ^a   Kaplan, M J ^b  

^a LUND UNIVERSITY   (Sweden)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

SLE; CVD; Immune mechanisms; Immunotherapy

Indexed keywords

AUTOANTIBODY; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; NEOPTERIN;

ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); HUMAN; LYMPHOCYTE; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; AUTOIMMUNITY; COMPLICATION; HEART DISEASES; HYPERCHOLESTEROLEMIA; IMMUNOLOGY; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; PROCEDURES;

ATHEROSCLEROSIS; AUTOIMMUNITY; HEART DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84944698647     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12357     Document Type: Review

References (102)

1. Gurevitz SL, Snyder JA, Wessel EK, Frey J, Williamson BA. Systemic lupus erythematosus: a review of the disease and treatment options. Consult Pharm 2013; 28: 110-21.
2. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008; 17: 371-5.
3. Lerang K, Gilboe IM, Steinar Thelle D, Gran J. Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study. Lupus 2014; 23: 1546-52.
4. Elfving P, Puolakka K, Kautiainen H, Virta L, Pohjolainen T, Kaipiainen-Seppanen O. Mortality and causes of death among incident cases of systemic lupus erythematosus in Finland 2000-2008. Lupus 2014; 23: 1430-4.
5. Thomas G, Mancini J, Jourde-Chiche N et al. Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. Arthritis Rheumatol 2014; 66: 2503-11.
6. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7.
7. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999; 26: 2363-8.
8. Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.
9. Asanuma Y, Oeser A, Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-15.
10. Yiu KH, Wang S, Mok MY et al. Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol 2009; 36: 2212-7.
11. Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, Camici PG. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J 2009; 30: 1837-43.
12. Lin CC, Ding HJ, Chen YW, Wang JJ, Ho ST, Kao A. Usefulness of technetium-99m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol 2003; 92: 157-61.
13. Kahlenberg JM, Kaplan MJ. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med 2013; 64: 249-63.
14. Enocsson H, Sjowall C, Kastbom A et al. Association of serum C-reactive protein levels with lupus disease activity in the absence of measurable interferon-alpha and a C-reactive protein gene variant. Arthritis Rheumatol 2014; 66: 1568-73.
15. Mak A, Kow NY. Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. Biomed Res Int 2014; 2014: 178721.
16. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
17. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest 2013; 123: 27-36.
18. Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 2008; 263: 464-78.
19. Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: 202.
20. Van Vre EA, Ait-Oufella H, Tedgui A, Mallat Z. Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 887-93.
21. Colonna L, Lood C, Elkon KB. Beyond apoptosis in lupus. Curr Opin Rheumatol 2014; 26: 459-66.
22. Ait-Oufella H, Kinugawa K, Zoll J et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation 2007; 115: 2168-77.
23. Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice. Arterioscler Thromb Vasc Biol 2008; 28: 1421-8.
24. Bhatia VK, Yun S, Leung V et al. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol 2007; 170: 416-26.
25. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001; 12: 383-9.
26. Rajagopalan S, Somers EC, Brook RD et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004; 103: 3677-83.
27. Renaudineau Y, Dugue C, Dueymes M, Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002; 1: 365-72.
28. Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus 2011; 20: 5-13.
29. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
30. Alarcon-Segovia D, Deleze M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-65.
31. Svenungsson E, Jensen-Urstad K, Heimburger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-93.
32. Gustafsson J, Gunnarsson I, Borjesson O et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther 2009; 11: R186.
33. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development-clinical and animal studies. Clin Chim Acta 2004; 348: 1-8.
34. Nilsson J, Kovanen PT. Will autoantibodies help to determine severity and progression of atherosclerosis? Curr Opin Lipidol 2004; 15: 499-503.
35. Binder CJ. Natural IgM antibodies against oxidation-specific epitopes. J Clin Immunol 2010; 30(Suppl 1): S56-60.
36. Binder CJ, Horkko S, Dewan A et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736-43.
37. Faria-Neto JR, Chyu KY, Li X et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006; 189: 83-90.
38. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 120: 417-26.
39. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 2000; 97: 1184-9.
40. Anania C, Gustafsson T, Hua X et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R214.
41. Fredrikson GN, Anand DV, Hopkins D et al. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia 2009; 52: 1426-33.
42. Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah PK, Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007; 194: e188-92.
43. Sjogren P, Fredrikson GN, Samnegard A et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 2008; 29: 2218-26.
44. Schiopu A, Bengtsson J, Soderberg I et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004; 110: 2047-52.
45. Schiopu A, Frendeus B, Jansson B et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 2007; 50: 2313-8.
46. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res 2012; 110: 875-88.
47. Cotoi OS, Duner P, Ko N et al. Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arterioscler Thromb Vasc Biol 2014; 34: 202-10.
48. Tyden H, Lood C, Gullstrand B et al. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology 2013; 52: 2048-55.
49. Radic M, Marion TN. Neutrophil extracellular chromatin traps connect innate immune response to autoimmunity. Semin Immunopathol 2013; 35: 465-80.
50. Gupta AK, Joshi MB, Philippova M et al. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett 2010; 584: 3193-7.
51. Carmona-Rivera C, Zhao W, Yalavarthi S, Kaplan MJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis 2014; doi: 10.1136/annrheumdis-2013-204837. [Epub ahead of print].
52. Saffarzadeh M, Juenemann C, Queisser MA et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 2012; 7: e32366.
53. Villanueva E, Yalavarthi S, Berthier CC et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011; 187: 538-52.
54. Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. Semin Immunopathol 2013; 35: 455-63.
55. Smith CK, Vivekanandan-Giri A, Tang C et al. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol 2014; 66: 2532-44.
56. Knight JS, Subramanian V, O'Dell AA et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis 2014; pii: annrheumdis-2014-205365.
57. Li Y, Lee PY, Reeves WH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz) 2010; 58: 355-64.
58. Li J, Fu Q, Cui H et al. Interferon-alpha priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-alpha and atherosclerosis in lupus. Arthritis Rheum 2011; 63: 492-502.
59. Reiss AB, Anwar K, Merrill JT et al. Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatol Int 2010; 30: 591-8.
60. Reiss AB, Wan DW, Anwar K et al. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med (Maywood) 2009; 234: 354-60.
61. Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med 2002; 195: 1167-74.
62. Zhao M, Wigren M, Duner P et al. FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol 2010; 184: 2253-60.
63. Rho YH, Solus J, Raggi P et al. Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63: 535-41.
64. Santos LL, Morand EF. Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta 2009; 399: 1-7.
65. Sanchez E, Gomez LM, Lopez-Nevot MA et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun 2006; 7: 433-6.
66. Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity 2010; 43: 84-97.
67. Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res 2014; 114: 1743-56.
68. Mak A, Kow NY. The pathology of T cells in systemic lupus erythematosus. J Immunol Res 2014; 2014: 419029.
69. Kow NY, Mak A. Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus. Clin Dev Immunol 2013; 2013: 245928.
70. Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-14.
71. Jury EC, Kabouridis PS, Flores-Borja F, Mageed RA, Isenberg DA. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 2004; 113: 1176-87.
72. Jury EC, Isenberg DA, Mauri C, Ehrenstein MR. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 2006; 177: 7416-22.
73. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 2011; 127: 303-12; quiz 13-4.
74. Ardoin SP, Schanberg LE, Sandborg C et al. Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort. Lupus 2010; 19: 1315-25.
75. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 589-93.
76. Shin MS, Lee N, Kang I. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol 2011; 23: 444-8.
77. Shah K, Lee WW, Lee SH et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R53.
78. Akahoshi M, Nakashima H, Tanaka Y et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1644-8.
79. Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 Cells in Atherosclerosis: subtle and Contextual Roles. Arterioscler Thromb Vasc Biol 2015; 35: 258-64.
80. Simon T, Taleb S, Danchin N et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J 2013; 34: 570-7.
81. Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007; 601: 113-9.
82. Golding A, Hasni S, Illei G, Shevach EM. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum 2013; 65: 2898-906.
83. Mor A, Planer D, Luboshits G et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 893-900.
84. Wigren M, Bjorkbacka H, Andersson L et al. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler Thromb Vasc Biol 2012; 32: 2000-4.
85. Ait-Oufella H, Salomon BL, Potteaux S et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-80.
86. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol 2012; 8: 214-23.
87. Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol 2014; 192: 5459-68.
88. Bezalel S, Guri KM, Elbirt D, Asher I, Sthoeger ZM. Type I interferon signature in systemic lupus erythematosus. Isr Med Assoc J 2014; 16: 246-9.
89. Lood C, Amisten S, Gullstrand B et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010; 116: 1951-7.
90. Goossens P, Gijbels MJ, Zernecke A et al. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab 2010; 12: 142-53.
91. Thacker SG, Zhao W, Smith CK et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012; 64: 2975-85.
92. Ansell BJ. The two faces of the 'good' cholesterol. Clevel Clin J Med 2007; 74: 697-700, 3-5.
93. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-8.
94. Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012; 14: R155.
95. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991; 147: 117-23.
96. Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 118-28.
97. Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol 2012; 2012: 347141.
98. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 283-8.
99. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 969-79.
100. Heeschen C, Dimmeler S, Hamm CW et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109-14.
101. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-20.
102. Nilsson J, Lichtman A, Tedgui A. Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges. J Intern Med 2015; 278: 507-19.